Department of Gastroenterology, Alfred Health, Melbourne, Australia.
Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia.
Intern Med J. 2023 Nov;53(11):2065-2072. doi: 10.1111/imj.16055. Epub 2023 Apr 18.
Non-alcoholic fatty liver disease (NAFLD) is a major healthcare burden. Real-world outcomes in dedicated tertiary care settings in Australia remain unknown.
To evaluate the initial outcomes of patients referred to a dedicated multidisciplinary tertiary care NAFLD clinic.
Retrospective review of all adult patients with NAFLD who attended a dedicated tertiary care NAFLD clinic between January 2018 and February 2020 and who had two clinic visits and FibroScans at least 12 months apart. Demographic and health-related clinical and laboratory data were extracted from electronic medical records. Key outcome measures were serum liver chemistries, liver stiffness measurement (LSM) and weight control at 12 months.
A total of 137 patients with NAFLD were included. Median (interquartile range (IQR)) follow-up time was 392 days (343-497 days). One hundred and eleven patients (81%) achieved weight control (i.e. weight loss or stability). Markers of liver disease activity were significantly improved, including median (IQR) serum alanine aminotransferase (48 (33-76) vs 41 (26-60) U/L, P = 0.009) and aspartate aminotransferase (35 (26-54) vs 32 (25-53) U/L, P = 0.020). Median (IQR) LSM across the whole cohort was significantly improved (8.4 (5.3-11.8) vs 7.0 (4.9-10.1) kPa, P = 0.001). No significant reduction was observed in mean body weight or the frequency of metabolic risk factors.
This study highlights a new model of care for patients with NAFLD and demonstrates promising initial outcomes in relation to significant reductions in markers of liver disease severity. Although most patients achieved weight control, further refinements are needed to achieve significant weight reduction including more frequent and structured dietetic and/or pharmacotherapeutic interventions.
非酒精性脂肪性肝病(NAFLD)是一个主要的医疗保健负担。在澳大利亚专门的三级保健机构中,真实世界的结果仍不清楚。
评估专门的多学科三级保健 NAFLD 诊所转诊患者的初始结果。
回顾性分析 2018 年 1 月至 2020 年 2 月期间在专门的三级保健 NAFLD 诊所就诊的所有成年 NAFLD 患者,这些患者至少相隔 12 个月进行了两次门诊就诊和 FibroScan。从电子病历中提取人口统计学和与健康相关的临床及实验室数据。主要结局指标为血清肝功能指标、肝硬度测量值(LSM)和 12 个月时的体重控制情况。
共纳入 137 例 NAFLD 患者。中位(四分位距(IQR))随访时间为 392 天(343-497 天)。111 例(81%)患者达到体重控制(即体重减轻或稳定)。肝病活动的标志物明显改善,包括中位(IQR)血清丙氨酸氨基转移酶(48(33-76)比 41(26-60)U/L,P=0.009)和天冬氨酸氨基转移酶(35(26-54)比 32(25-53)U/L,P=0.020)。整个队列的中位(IQR)LSM 明显改善(8.4(5.3-11.8)比 7.0(4.9-10.1)kPa,P=0.001)。平均体重或代谢风险因素的频率没有明显降低。
本研究突出了一种新的 NAFLD 患者护理模式,并展示了与肝疾病严重程度标志物显著降低相关的有前景的初始结果。尽管大多数患者实现了体重控制,但仍需要进一步改进,以实现显著的体重减轻,包括更频繁和更有针对性的饮食和/或药物治疗干预。